2025 was a year of real momentum — for the industry and for us at Abselion.
Across pharma and biotech, teams continued working with broader and increasingly complex modality portfolios. As development timelines accelerated, the need for dependable, practical analytics became even more evident. Clear, confident data now plays a central role in shaping early research and development decisions.
I’m incredibly proud of what our team achieved this past year. We expanded our assay offerings, strengthened the Amperia™ platform, and supported a growing number of groups navigating fast-moving pipelines. Our presence across conferences, collaborations, and publications also grew, reflecting both our progress and the trust placed in us by our community.
Looking ahead to 2026, one need is becoming more apparent: scientists are seeking fit-for-purpose tools that bring clarity without unnecessary complexity. Whether in expression screening, vector optimisation, or early development, reliable and accessible measurements will continue to help teams maintain momentum and make confident decisions.
To our partners, collaborators, and customers — thank you for your continued support and insights throughout 2025.
And to the Abselion team — thank you for your dedication, creativity, and hard work. We achieved a great deal together this year, and I look forward to everything we will explore in 2026.
Wishing everyone a positive and productive start to the new year.
Ruizhi Wang
CEO & Founder, Abselion